Citations

Clear

37 citation(s) found for "Torgerson, C A".

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report
Winestone, Lena E. , Logan, Brent R. , Liu, Xuerong , Williams, Olatundun , Dunn, Elizabeth A. , Thakar, Monica S. , Kidd, Sharon A. , Dorsey, Morna J. , O'Reilly, R, Kapoor, Neena , Kapadia, Malika , Jyonouchi, Soma , Chandra, Sharat , Chellapandian, Deepak , Chaudhury, Sonali , Chen, Karin , Rayes, Ahmad , Quigg, Troy C. , Teira, Pierre , Gillio, Alfred P. , Eissa, Hesham, Knutsen, Alan P., Aquino, Victor M. , Shereck, Evan , Lugt, Mark T. Vander , Rozmus, Jacob, Yu, Lolie C. , Shah, Ami J. , Joshi, Avni Y. , Buckley, Rebecca H. , Oved, Joseph H. , Azim, Hisham Abdel, Martinez, Caridad , Sullivan, Kathleen E. , Bleesing, Jack J., Madden, Lisa, Shenoy, Shalini , Seroogy, Christine M. , Rubin, Tamar N. , Licata, Jennifer, Andolina, Jeffrey R. , Burroughs, Lauri M. , Leiding, Jennifer W. , Marsh, Rebecca , Pai, Sung‐Yun , Torgerson, Troy R. , Heimall, Jennifer , Griffith, Linda M. , Puck, Jennifer M. , Dvorak, Christopher C. , Cowan, Morton J. , Liu, Xuerong , Mousallem, Talal , Dorsey, Morna J , O'Reilly, Richard J , Kapoor, Neena , Forbes Satter, Lisa R , Kapadia, Malika , Chandra, Sharat , Ebens, Christen L , Chellapandian, Deepakbabu , Chaudhury, Sonali , Chen, Karin , Dávila Saldaña, Blachy J , Rayes, Ahmad , Quigg, Troy C , Chandrakasan, Shanmuganathan , Bednarski, Jeffrey J , DeSantes, Kenneth B , Teira, Pierre , Gillio, Alfred P , Eissa, Hesham , Aquino, Victor M , Shereck, Evan B , Moore, Theodore Bruce , Caywood, Emi H , Vander Lugt, Mark T , Rozmus, Jacob , Broglie, Larisa A , Yu, Lolie C. , Shah, Ami J , Joshi, Avni Y , Buckley, Rebecca H , Dara, Jasmeen , Oved, Joseph H , Abdel Azim, Hisham , Martinez, Caridad , Prockop, Susan E , Sullivan, Kathleen E , Bleesing, Jack J , Keller, Michael D , Madden, Lisa M , Parikh, Suhag , Shenoy, Shalini , Seroogy, Christine M , Rubin, Tamar , Licata, Jennifer , Andolina, Jeffrey R , Kohn, Donald B , Burroughs, Lauri M , Leiding, Jennifer W , Marsh, Rebecca A , Notarangelo, Luigi D , Pai, Sung-Yun , Torgerson, Troy R , Pulsipher, Michael A. , Heimall, Jennifer , Cuvelier, Geoffrey D E , Griffith, Linda M , Puck, Jennifer M , Dvorak, Christopher C , Cowan, Morton J , Haddad, Elie , Winestone, Lena E , Satter, Lisa Forbes , Ebens, Christen L. , Saldaña, Blachy J. Dávila , Chandrakasan, Shanmuganathan , Knutsen, Alan P. , Broglie, Larisa , Dara, Jasmeen , Abdel‐Azim, Hisham , Prockop, Susan E. , Bleesing, Jack , Keller, Michael D. , Parikh, Suhag , Kohn, Donald B. , Cuvelier, Geoff D.E. , Haddad, Élie

Mayo Clinic

Journal of Human Immunity | July 7, 2026 | Volume: 2 | Issue: 5 | Pages: No page available

10.70962/jhi.20250231 | PMID 42416786 Get It

Black race and Hispanic ethnicity are associated with higher mortality in severe combined immunodeficiency (SCID) following hematopoietic cell transplantation (HCT), though mechanisms remain unclear. We evaluated 796 children with SCID who received nonsibling HCT between 1982 and 2020 using data from the Primary Immune Deficiency Treatment Consortium. Overall survival for Black (aHR 2.47, 95%CI 1.64, 3.71) and Asian/Pacific Islander patients (aHR 1.82, 95%CI 1.00, 3.30) was significantly lower compared with non-Hispanic White patients, while Hispanic patients had lower event-free survival (aHR 1.83, 95%CI 1.27, 2.63) compared with non-Hispanic White patients. Even after adjusting for age and infection, Black patients with SCID had more than twofold hazard of death compared with non-Hispanic White patients. NBS was associated with earlier diagnosis, reduced infection at HCT, and elimination of survival disparities between Black and non-Hispanic White patients. These findings suggest that universal, system-level interventions such as NBS can mitigate disparities in outcomes for children with SCID.
Factors affecting trainees’ preferred timing of clinical clerkships during MD-PhD training
Weng, Jessica , Cornelius, Katherine , Hurley, Lisa M., Hu, Leland , Ensign, Shannon P. Fortin , Torgerson, Rochelle R. , Maleszewski, Joseph J. , Horazdovsky, Bruce , Weroha, Saravut J., Trentadue, Taylor P , Weng, Jessica , Bouchal, Samantha M , Cornelius, Katherine E , Hu, Leland S , Ensign, Shannon P. Fortin , Maleszewski, Joseph J , Horazdovsky, Bruce F , Kaufmann, Scott H , Weroha, S John , Schimmenti, Lisa A , Trentadue, Taylor P. , Bouchal, Samantha M. , Kaufmann, Scott H. , Schimmenti, Lisa A.

Mayo Clinic

No container title available | May 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.10.26352845 | PMID 42180366 Get It

Abstract M.D.-Ph.D. programs in the United States have traditionally followed a “2- n -2” curricular model, with the graduate phase occurring between the pre-clerkship and clerkship portions of medical training. While well established, this format can limit trainee autonomy in shaping their physician-scientist training trajectories. In response, some programs have introduced a “3- n -1” model, allowing students to complete clerkships before beginning Ph.D. training. Our institution implemented multiple flexible curricula in 2017. Understanding why trainees choose one pathway is important as programs consider implementing more adaptable training structures. To investigate these factors, we surveyed M.D.-Ph.D. students at our institution, which offers multiple flexible curricular alternatives, about contributions to their curricular decisions. Responses supported that trainees weigh considerations across medical education, scientific development, and integrated physician-scientist training domains. Although the traditional pathway was a popular option, most students pursued one of the flexible pathways. Our findings suggest that introducing flexibility in the timing of undergraduate medical education and graduate training can support diverse educational, logistical, and personal priorities while maintaining the rigor of physician-scientist training. Offering multiple pathways empowers trainees to design trajectories that best fit their needs. Continued longitudinal studies are needed to assess the long-term impacts of flexible curricula on physician-scientist career outcomes.
Contact Sensitivities in Vulvar Disease
Dyck, Rayna M., Farmer, Sara A., Torgerson, Rochelle R.

Mayo Clinic

Dermatitis® | April 16, 2026 | Volume: 19 | Issue: 3 | Pages: 175-175

10.2310/6620.2008.00005ee Get It

CONTACT SENSITIVITIES IN ORAL DISEASE
Torgerson, Rochelle R. , Davis, Mark Denis P., Bruce, Alison J., Farmer, Sara A., Rogers, Roy S., Davis, Mark D.P. , Rogers, Roy S.

Mayo Clinic

Dermatitis® | March 2, 2026 | Volume: 16 | Issue: 2 | Pages: 100-100

10.2310/derm.1.2005.2083 Get It

Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Alexander, Jessie L. , Saldaña, Blachy J. Dávila , Brazauskas, Ruta , Dammalapati, Sravya Gethika, Griffith, Linda M. , Shah, Ami J. , Shimano, Kristin A. , Ochs, Hans D., Bleesing, Jack , Ebens, Christen L. , Kapadia, Malika, Bauchat, Andrea , Oved, Joseph H. , Eissa, Hesham, Lust, Hannah , Haines, Hilary , Rayes, Ahmad , Madden, Lisa, Shereck, Evan , Miller, Holly, Martinez, Caridad , Rozmus, Jacob, Yu, Lolie C. , Chellapandian, Deepak , Aquino, Victor M., Knutsen, Alan P. , Chong, Hey , Chopek, Ashley, Gillio, Alfred P. , Joshi, Avni Y. , Rangarajan, Hemalatha G. , Andolina, Jeffrey R. , Lugt, Mark T. Vander , Prockop, Susan E. , Shyr, David C. , Sullivan, Kathleen E. , Weinacht, Katja G. , Torgerson, Troy R. , Marsh, Rebecca , Dvorak, Christopher C. , Heimall, Jennifer , Leiding, Jennifer W. , Puck, Jennifer M. , Rawlings, David J. , Cowan, Morton J. , Petrović, Aleksandra , Pai, Sung‐Yun , Burroughs, Lauri M. , Dávila Saldaña, Blachy J , Oved, Joseph H , Lust, Hannah , Rayes, Ahmad , Forbes Satter, Lisa R , Bednarski, Jeffrey J , Chellapandian, Deepakbabu , Joshi, Avni, Rangarajan, Hemalatha G , Andolina, Jeffrey R , Prockop, Susan E , Parikh, Suhag , Torgerson, Troy R , Chan, Alice Y , Haddad, Elie , Pulsipher, Michael A. , Leiding, Jennifer W , Kohn, Donald B , Puck, Jennifer M , Notarangelo, Luigi D , Pai, Sung-Yun , Burroughs, Lauri M , Ebens, Christen L , Dvorak, Christopher C , Shimano, Kristin A , Shah, Ami J , Ochs, Hans D., Kapoor, Neena R. , Keller, Michael D. , Chandrakasan, Shanmuganathan , Talano, Julie‐An , Satter, Lisa Forbes , Moore, Theodore Bruce , DeSantes, Kenneth B , Parikh, Suhag , Haddad, Élie , Kohn, Donald B.

Mayo Clinic

Blood Advances | December 5, 2025 | Volume: 10 | Issue: 5 | Pages: 1783-1798

10.1182/bloodadvances.2025017662 | PMID 41346295 Get It

Abstract Wiskott-Aldrich syndrome (WAS), an X-linked disorder characterized by immunodeficiency, thrombocytopenia, autoimmunity, and malignancy, can be effectively treated with allogeneic hematopoietic cell transplantation (HCT). Older age at HCT and mismatched donors are known to affect overall survival (OS). However, the influence of specific clinical manifestations or WAS variant class on OS and factors associated with event-free survival (EFS) remain incompletely defined. We analyzed outcomes of 308 patients with WAS who underwent HCT at 37 institutions of the Primary Immune Deficiency Treatment Consortium from 1990 to 2018. With a median follow-up of 5.3 years, the 5-year OS and EFS were 87.2% and 79.7%, respectively. Age ≥5 years, donor type, and a pre-HCT history of severe infection had a negative impact on OS and EFS, whereas pre-HCT autoimmunity had no impact. Reduced-intensity regimens were associated with lower T-cell and myeloid donor chimerism, particularly when non–busulfan-based regimens were used. Low myeloid donor chimerism was associated with lower platelet counts. Mixed chimerism was not consistently associated with post-HCT autoimmunity. Patients with class I (exon 1-2 missense and intron 5 hot spot variants) and class II variants (all others) had similar pre-HCT clinical symptom severity and no difference in OS, EFS, or platelet recovery post-HCT. In conclusion, our study showed excellent long-term OS and EFS after HCT for WAS, highlighting the importance of early HCT, before the development of severe infections. We confirmed that HCT using busulfan-based conditioning was associated with improved donor chimerism and platelet recovery. This trial was registered at www.clinicaltrials.gov as NCT02064933.
377 Decreasing Trainer Burnout & Human-Derived Laboratory Errors
Olson, Kellie, Torgerson, Tammy, Ott, Katie, Zeien, Tracey, Montgomery, Roy, Wilson, Mary Edythe , Montgomery, Roy

Mayo Clinic

American Journal of Clinical Pathology | November 12, 2025 | Volume: 164 | Issue: Supplement_1 | Pages: No page available

10.1093/ajcp/aqaf121.305 Get It

Abstract Introduction/Objective Burnout among trainers can lead to increased human-derived laboratory errors (HDLEs), which can negatively affect patient outcomes. Through implemented improvement strategies, trainer burnout and HDLEs were reduced without impacting the trainee burnout by creating a core training group to ensure consistency in training and providing additional training tools. Methods/Case Report Burnout was assessed using a survey from the Burnout Assessment Tool1. This survey indicates burnout as a numerical score and was given to trainers and trainees at 3 intervals. Pre-implementation concluded trainer burnout average score was 2.47. HDLEs were categorized and totaled in conjunction with the burnout surveys. Pre-implementation data for HDLEs showed 14% were associated with a training event and 14% were associated with a process change that did not have a training event. Results: Conclusion Final data showed a decrease in average burnout score for trainers (pre=2.47, post=2.26). Trainee score was not statistically different. Post-implementation data of HDLEs showed 6% were associated with a training event and 0% were associated with a process change that didn’t have a training event. In review of the project, standardization of training, proper communication of process changes decreases average burnout of trainers and reduces the amount of HDLEs associated with training and process changes.
Body mass index and subsequent fracture risk: a meta-analysis to update FRAX
Harvey, Nicholas C. , Johansson, Helena, McCloskey, Eugène , Liu, Enwu , Åkesson, Kristina , Anderson, Fred, Bager, Cecilie L. , Christiansen, Claus, Cooper, Cyrus , Crandall, Carolyn , Cummings, Steven R. , Dawson‐Hughes, Bess , Eisman, John A. , Fujita, Yuki , Fujiwara, Saeko , Glüer, Claus‐Christian , Guðnason, Vilmundur , Hall, Jill, Huisman, Martijn , Iki, Masayuki , Ish‐Shalom, Sophia, Koromani, Fjorda , Kröger, Heikki , Esfahani, Zahra , McGuigan, Fiona E. , Mellström, Dan, Merlijn, Thomas , Nguyen, Tuan V., Ohlsson, Claes , Pasco, Julie A. , Rivadeneira, Fernando, Schei, Berit , Shiroma, Eric J. , Siggeirsdóttir, Kristín , Swart, Karin M. A. , Tamaki, Junko , Staa, Tjeerd van , Wareham, Nicholas J, Yoshimura, Noriko , Zwart, Marta , Kanis, John A, McCloskey, Eugene V , Åkesson, Kristina E , Biver, Emmanuel , Center, Jacqueline R , Cooper, Cyrus , Crandall, Carolyn J , Dawson-Hughes, Bess , Dufour, Alyssa B , Eisman, John A , Ferrari, Serge , Hans, Didier B. , Iki, Masayuki , Karlsson, Magnus K , Khosla, Sundeep , Kiel, Douglas P , Koromani, Fjorda , Kwok, Timothy , Lamy, Olivier , Larijani, Bagher , McGuigan, Fiona E A , Merlijn, Thomas , Ohlsson, Claes , Orwoll, Eric S , Simonsick, Eleanor Marie , Sund, Reijo , Szulc, Pawel , Tamaki, Junko , Wright, Nicole C , Zillikens, M. Carola , Lorentzon, Mattias , Leslie, William D , Azagra, Rafael , Beaudart, Charlotte , Bischoff‐Ferrari, Heike A. , Biver, Emmanuel , Bruyère, Olivier , Cauley, Jane A. , Chapurlat, Roland D , Silva, José António Pereira da , Díez‐Pérez, Adolfo , Elders, Petra J. M. , Ferrari, Serge , Goldshtein, Inbal , Goltzman, David , Hall, Jill, Hoff, Mari , Hollick, Rosemary J , Jones, Graeme , Khosla, Sundeep , Kiel, Douglas P. , Koh, Woon‐Puay , Kotowicz, Mark A. , Langhammer, Arnulf , Lippuner, Kurt , Nordström, Anna , Nordström, Peter , O’Neill, Terence W , Obermayer-Pietsch, Barbara Maria , Orwoll, Eric , Rivadeneira, Fernando , Schott, Anne‐Marie , Sornay‐Rendu, Elisabeth , Szulc, Paweł , Torgerson, David John , Schoor, Natasja M. van , Vila, Joan , Vandenput, Liesbeth , Lorentzon, Mattias , Leslie, William D. , Kanis, John A.

Mayo Clinic

Journal of Bone and Mineral Research | August 12, 2025 | Volume: 40 | Issue: 10 | Pages: 1144-1155

10.1093/jbmr/zjaf091 | PMID 40795319 Get It

Abstract The aim of this international meta-analysis was to quantify the predictive value of BMI for incident fracture and relationship of this risk with age, sex, follow-up time, and BMD. A total of 1 667 922 men and women from 32 countries (63 cohorts), followed for a total of 16.0 million person-years were studied. 293 325 had FN BMD measured (2.2 million person-years follow-up). An extended Poisson model in each cohort was used to investigate relationships between WHO-defined BMI categories (Underweight: <18.5 kg/m2; Normal: 18.5-24.9 kg/m2; Overweight: 25.0-29.9 kg/m2; Obese I: 30.0-34.9 kg/m2; Obese II: ≥35.0 kg/m2) and risk of incident osteoporotic, major osteoporotic and hip fracture (HF). Inverse-variance weighted β-coefficients were used to merge the cohort-specific results. For the subset with BMD available, in models adjusted for age and follow-up time, the hazard ratio (95% CI) for HF comparing underweight with normal weight was 2.35 (2.10-2.60) in women and for men was 2.45 (1.90-3.17). Hip fracture risk was lower in overweight and obese categories compared to normal weight [obese II vs normal: women 0.66 (0.55-0.80); men 0.91 (0.66-1.26)]. Further adjustment for FN BMD T-score attenuated the increased risk associated with underweight [underweight vs normal: women 1.69 (1.47-1.96); men 1.46 (1.00-2.13)]. In these models, the protective effects of overweight and obesity were attenuated, and in both sexes, the direction of association reversed to higher fracture risk in Obese II category [Obese II vs Normal: women 1.24 (0.97-1.58); men 1.70 (1.06-2.75)]. Results were similar for other fracture outcomes. Underweight is a risk factor for fracture in both men and women regardless of adjustment for BMD. However, while overweight/obesity appeared protective in base models, they became risk factors after additional adjustment for FN BMD, particularly in the Obese II category. This effect in the highest BMI categories was of greater magnitude in men than women. These results will inform the second iteration of FRAX®.
Anetoderma in the Setting of a Hematologic Abnormality and COVID-19 Infection
Xu, Kathryn , Proffer, Sydney L. , Torgerson, Rochelle R. , Peters, Margot S. , Xu, Kathryn K

Mayo Clinic

The American Journal of Dermatopathology | August 14, 2024 | Volume: 46 | Issue: 11 | Pages: e104-e105

10.1097/dad.0000000000002823 | PMID 39141716 Get It

Abstract: Anetoderma is an uncommonly reported dermatosis clinically characterized by discrete skin lesions resulting from elastic fiber loss within the dermis. Although primary anetoderma has been considered idiopathic, a range of associated disorders, particularly prothrombotic abnormalities, have been reported. We present a 79-year-old woman with a heterozygous Factor V Leiden mutation who developed anetoderma shortly after COVID-19 infection complicated by a thromboembolic event. Our patient adds to the literature on the occurrence of anetoderma in the setting of infection and/or a prothrombotic disorder.
Treatment of lichen sclerosus with hydroxychloroquine: a Mayo Clinic experience
Akpala, Christeebella O. , Tekin, Burak , Torgerson, Rochelle R. , Wetter, David A. , Nguyen, Giang Huong , Akpala, Christeebella O , Nguyen, Giang H

Mayo Clinic

International Journal of Dermatology | July 20, 2024 | Volume: 63 | Issue: 10 | Pages: No page available

10.1111/ijd.17394 | PMID 39032011 Get It

AbstractBackgroundThere is a dearth of studies investigating the efficacy of hydroxychloroquine in the treatment of either anogenital lichen sclerosus or extragenital lichen sclerosus, a condition that, if left untreated, could lead to a greater degree of scarring and malignant transformation.ObjectiveThis study aims to analyze the demographic characteristics, clinicopathological features, treatment response, and outcomes of patients diagnosed with either anogenital or extragenital lichen sclerosus who received hydroxychloroquine therapy.MethodsA retrospective analysis was conducted involving 70 patients diagnosed with lichen sclerosus who underwent treatment with hydroxychloroquine at our institution between 2018 and 2023.ResultsAmong the cohort, 67 patients were female, and 3 were male. Extragenital lichen sclerosus was diagnosed in 23 patients, with 16 exhibiting concomitant morphea overlap. Itching was the predominant clinical presentation (67%). A notable proportion of patients (36%) had a connective tissue disorder, prompting hydroxychloroquine therapy. Among the 30 patients treated solely for lichen sclerosus, 21 demonstrated response and 9 had no response. From a broader comparison of response to hydroxychloroquine, the overall anogenital response rate was 84.6% as opposed to 50% in extragenital lichen sclerosus. The median time to initial response was 4 months. Adverse effects, predominantly mild, were observed in 10 (14.3%) patients.LimitationThis study is constrained by its retrospective nature and reliance on data from a single center, resulting in a limited sample size.ConclusionHydroxychloroquine demonstrates promise as a therapeutic option for anogenital lichen sclerosus because of its favorable response rates and low incidence of adverse effects. However, further investigations, including larger‐scale or prospective studies, are imperative to ascertain its definitive efficacy.
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
Leiding, Jennifer W. , Arnold, Danielle E. , Parikh, Suhag , Logan, Brent R. , Marsh, Rebecca , Griffith, Linda M. , Wu, Ruizhe , Kidd, Sharon A. , Mallhi, Kanwaldeep , Chellapandian, Deepak , Lim, Stephanie Si , Grunebaum, Eyal , Falcone, Emilia Liana , Grossman, Debbi, Prasad, Vinod K. , Heimall, Jennifer , Burroughs, Lauri M. , Bleesing, Jack , Kapoor, Neena , Dara, Jasmeen , Williams, Olatundun , Kapadia, Malika, Oshrine, Benjamin , Rayes, Ahmad , Chong, Hey , Satter, Lisa Forbes , Martinez, Caridad , Lugt, Mark T. Vander , Yu, Lolie C. , Joshi, Avni Y. , Prockop, Susan E. , Aquino, Victor , Madden, Lisa, Milner, Jordan , Rangarajan, Hemalatha G. , Shah, Ami J. , Gillio, Alfred P. , Knutsen, Alan P. , Miller, Holly, Graham, Pamela, Bauchat, Andrea , Bunin, Nancy , Teira, Pierre , Petrović, Aleksandra , Chandra, Sharat , Abdel‐Azim, Hisham , Birbrayer, Olga, Cowan, Morton J. , Dvorak, Christopher C. , Pai, Sung‐Yun , Puck, Jennifer M. , Torgerson, Troy R. , Kang, Elizabeth M. , Si Lim, Stephanie J , Murguia-Favela, Luis , Prasad, Vinod K , Touzot, Fabien , Bednarski, Jeffrey J , Cuvelier, Geoffrey D E , Forbes Satter, Lisa R , Martinez, Caridad , Joshi, Avni, Prockop, Susan E , Dávila Saldaña, Blachy J , Broglie, Larisa A , Ebens, Christen L , Milner, Jordan , Rangarajan, Hemalatha G , Chandra, Sharat , Dorsey, Morna J , Cowan, Morton J , Dvorak, Christopher C , Haddad, Elie , Kohn, Donald B , Notarangelo, Luigi D , Puck, Jennifer M , Pulsipher, Michael A. , Torgerson, Troy R , Malech, Harry L , Kang, Elizabeth M , Parikh, Suhag , Leiding, Jennifer W , Shah, Ami J , Dara, Jasmeen , Cuvelier, Geoff D.E. , Chandrakasan, Shanmuganathan , Saldaña, Blachy J. Dávila , Broglie, Larisa , Ebens, Christen L. , DeSantes, Kenneth B , Moore, Theodore Bruce , Graham, Pamela, Dorsey, Morna J. , Haddad, Élie , Kohn, Donald B. , Malech, Harry L.

Mayo Clinic

Blood | August 10, 2023 | Volume: 142 | Issue: 24 | Pages: 2105-2118

10.1182/blood.2022019586 | PMID 37562003 Get It

Abstract Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT) enrolled from 2004 to 2018 or with HCT from 1996 to 2018. Median follow-up after HCT was 3.7 years with a 3-year overall survival of 82% and event-free survival of 69%. In a multivariate analysis, a Lansky/Karnofsky score <90 and use of HLA-mismatched donors negatively affected survival. Age, genotype, and oxidase status did not affect outcomes. Before HCT, patients had higher infection density, higher frequency of noninfectious lung and liver diseases, and more steroid use than conventionally treated patients; however, these issues did not adversely affect HCT survival. Presence of pre-HCT inflammatory conditions was associated with chronic graft-versus-host disease. Graft failure or receipt of a second HCT occurred in 17.6% of the patients and was associated with melphalan-based conditioning and/or early mixed chimerism. At 3 to 5 years after HCT, patients had improved growth and nutrition, resolved infections and inflammatory disease, and lower rates of antimicrobial prophylaxis or corticosteroid use compared with both their baseline and those of conventionally treated patients. HCT leads to durable resolution of CGD symptoms and lowers the burden of the disease. Patients with active infection or inflammation are candidates for transplants; HCT should be considered before the development of comorbidities that could affect performance status. This trial was registered at www.clinicaltrials.gov as #NCT02082353.